Nanosys Licenses Nanowire Technology to QuantuMDx | GenomeWeb

NEW YORK (GenomeWeb News) – Nanosys today said that it has licensed patents and patent applications covering the use of nanowires for biosensors to QuantuMDx Group.

The non-exclusive pact allows QuantuMDx to use the technology worldwide for DNA sequencing and biomarker detection applications. In exchange, QuantuMDx paid Palo Alto, Calif.-based Nanosys an upfront license fee and will make downstream royalty payments.

Further terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.